ArticleRwanda journal of medicine and health sciences2025
Cardiometabolic Risk Marker Changes in Centrally Obese Women Using Depot Medroxyprogesterone Acetate (DMPA) in Kigali, Rwanda.
Article in Rwanda journal of medicine and health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathophysiological Consequences Associated with Hormonal Contraceptives Use in Sub-Saharan Africa: A Scoping Review.Open access journal of contraception · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hormonal contraceptives, such as depot medroxyprogesterone acetate (DMPA), are known to increase the risk of cardiometabolic disease, especially in obese users who are already at high risk. Objectives: This study aimed to evaluate changes in lipid profile, glycated hemoglobin (HbA1C), blood pressure (BP), and inflammatory markers over a 12-month follow-up in centrally obese women using DMPA in Rwanda. Methods: A prospective study involving 65 abdominally obese women (aged 15-49 years) was conducted at two family planning centres in Kigali. Measurements were taken at baseline, six months, and twelve months, including a lipid profile, HbA1c, BP, and high-sensitivity C-reactive protein (hs-CRP). Changes were analyzed using the Wilcoxon signed-rank test, with a significance level of 5%. Results: The study demonstrated significant changes in the median of cardiometabolic parameters over 12 months of DMPA use. WC increased from 96(41) to 99.5(44) cm, TG from 1.15(2.40) to 1.53(3.63) mmol/L, while HDL-c decreased from 1.09(1.55) to 0.90(0.99) mmol/L (all P=0.001). Lipid ratios also increased significantly, where the TC/HDL-c increased from 3.54(5.92) to 5.99(8.58), and LDL-c/HDL-c from 2.63(4.8) to 4.68(7.38) (P=0.001). Conclusion: Given these findings, assessing central obesity before initiating DMPA and performing cardiovascular risk evaluations every six months is recommended to mitigate adverse effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.